Status:
TERMINATED
A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
Lead Sponsor:
Emory University
Conditions:
Cytokines
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether or not the injection site of cytokines, or growth factors, has an effect on peripheral blood stem cell collection.
Detailed Description
The purpose of this study is to determine the preferred injection site for G-CSF and GM-CSF, which are cytokines, or growth factors. The doctor may also choose to use these growth factors in combinati...
Eligibility Criteria
Inclusion
- All patients undergoing autologous peripheral blood stem cell transplant (PBSC) for relapsed/refractory Hodgkin's disease, non-Hodgkin's lymphoma, or patients with myeloma. All patients must meet criteria for transplantation.
Exclusion
- Patients with active, invasive/systemic fungal infection.
- Patients who are pregnant or lactating females.
- Patients with active CNS malignant disease or life expectancy limited by diseases other than the disease for which the patient is being transplanted.
- Also, patients cannot have known hypersensitivity to either G-CSF or GM-CSF.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00646763
Start Date
April 1 2008
End Date
February 1 2011
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322